CY
CYCN.US Cyclerion Therapeutics Inc
- Market cap
- USD 2.25M
- P/E
- -
- P/B
- 3.15x
- ROE
- -16.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CYCN.US undervalued?
Graham numberThe Graham number of Cyclerion Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cyclerion Therapeutics Inc fundamental analysis
No fundamental analysis for Cyclerion Therapeutics Inc yet.
Cyclerion Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cyclerion Therapeutics Inc
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare ki…
Full company profileCyclerion Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cyclerion Therapeutics Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 4.51M | 2.30M | 3.32M | 297K | 0.00 | 2.00M | 2.07M | - |
| Gross Profit | -2.17M | -1.75M | -1.53M | -90.6M | -54.1M | 3.32M | -5.28M | -1.32M | 2.00M | 2.07M | - |
| Operating Income | -63.6M | -93.9M | -115M | -125M | -81.3M | -55.2M | -18.5M | -13.0M | -3.63M | -4.97M | -71.0M |
| EBITDA | -61.4M | -92.2M | -114M | -122M | -80.6M | -53.8M | -18.2M | -9.58M | -3.06M | -3.53M | -70.9M |
| Net Income | -63.6M | -93.9M | -115M | -123M | -77.8M | -51.6M | -44.1M | -5.26M | -3.06M | -3.53M | -68.5M |
| EPS | -325 | -482 | -591 | -629 | -358 | -185 | -142 | -16 | -8.50 | -7.66 | -5.06 |
| Balance Sheet | |||||||||||
| Total Assets | 3.88M | 5.47M | 7.40M | 186M | 115M | 59.3M | 18.1M | 13.4M | 9.58M | 9.99M | 462M |
| Total Liabilities | 10.6M | 14.0M | 17.8M | 88.7M | 55.9M | 11.1M | 7.63M | 2.09M | 725K | 900K | 45.6M |
| Shareholders' Equity | -6.76M | -8.57M | -10.4M | 97.7M | 59.5M | 48.2M | 10.5M | 11.3M | 8.85M | 9.09M | 417M |
| Cash & Short-term Investments | 0.00 | 0.00 | 0.00 | 97.6M | 54.4M | 54.0M | 13.4M | 7.57M | 3.23M | 3.24M | 456M |
| Total Debt | - | - | - | 73.9M | 45.7M | - | - | - | - | - | 1.27M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -49.9M | -81.2M | -97.5M | -102M | -72.5M | -36.5M | -40.6M | -21.2M | -4.33M | -3.31M | -65.9M |
| Capital Expenditure | 1.45M | 1.40M | 3.44M | 6.89M | 1.52M | 7.00K | 0.00 | 0.00 | 0.00 | 0.00 | 572K |
| Free Cash Flow | -51.3M | -82.6M | -101M | -109M | -74.0M | -36.5M | -40.6M | -21.2M | -4.33M | -3.31M | -66.3M |
| Ratios | |||||||||||
| ROE | - | - | - | -125.9% | -130.8% | -107.0% | -421.7% | -46.6% | -34.5% | -38.8% | -16.4% |
| ROA | -1,640.1% | -1,717.0% | -1,557.2% | -66.0% | -67.4% | -87.0% | -243.8% | -39.4% | -31.9% | -35.3% | -14.8% |
| Net Profit Margin | - | - | - | -2,729.3% | -3,388.6% | -1,555.6% | -14,841.1% | - | -152.9% | -170.1% | - |
| Debt to Equity | - | - | - | 0.76x | 0.77x | - | - | - | - | - | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cyclerion Therapeutics Inc dividends
Cyclerion Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:7 on Sep 9, 2026.
Who owns Cyclerion Therapeutics Inc
- Insiders 21.70%
- Institutions 70.86%
- Public & others 7.44%
- Shares outstanding 669K
- Free float 168K
Top funds holding CYCN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Growth Compy Commingled Pl S | 288K | 7.53% | 0.00% | Jul 2026 |
| Fidelity Growth Company Fund | 218K | 5.70% | 0.00% | Jul 2026 |
| Fidelity Growth Company K6 | 60.7K | 1.59% | 0.00% | Jul 2026 |
| Fidelity Series Growth Company | 57.3K | 1.50% | 0.00% | Jul 2026 |
| Vanguard Institutional Extnd Mkt Idx Tr | 30.9K | 0.81% | 0.00% | Jul 2026 |
| Fidelity Nasdaq Composite ETF | 21.3K | 0.56% | 0.00% | Aug 2026 |
| Fidelity Extended Market Index | 17.4K | 0.46% | -0.19% | Jul 2026 |
| LUX IM Global Medtech HX | 16.4K | 0.43% | 0.00% | Aug 2026 |
| Fidelity Small Cap Growth | 9.90K | 0.26% | 0.00% | Jun 2026 |
| Fidelity Small Cap Growth K6 | 4.98K | 0.13% | 0.00% | Jun 2026 |
| Extended Equity Market Fund E | 3.44K | 0.09% | 0.00% | Dec 2025 |
| Blackrock Extended Mkt Fund CF | 3.44K | 0.09% | 0.00% | May 2026 |
| Extended Equity Market Fund B | 3.44K | 0.09% | 0.00% | Dec 2025 |
| Fidelity Series Total Market Index | 3.37K | 0.09% | 0.00% | Jul 2026 |
| Dimensional US Sustainability Core 1 ETF | 3.32K | 0.09% | 0.00% | Aug 2026 |
| DFA US Vector Equity Class F | 3.09K | 0.08% | 0.00% | Jun 2026 |
| NT Ext Equity Mkt Index Fund - NL | 3.04K | 0.08% | +80.31% | Jun 2026 |
| Fidelity Select Health Care | 3.00K | 0.08% | 0.00% | Jul 2026 |
| BlackRock Extended Equity Market Fund K | 2.92K | 0.08% | -0.17% | Jun 2026 |
| Dimensional US Core Equity USD Acc | 2.38K | 0.06% | 0.00% | Jul 2026 |
Top institutions holding CYCN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Geode Capital Management, LLC | 84.6K | 2.21% | +95.26% | Mar 2026 |
| Citadel Advisors Llc | 59.8K | 1.56% | +227.45% | Jun 2026 |
| BlackRock Inc | 16.8K | 0.44% | 0.00% | Mar 2026 |
| Vanguard Capital Management, LLC | 16.1K | 0.42% | 0.00% | Mar 2026 |
| Dimensional Fund Advisors, Inc. | 11.7K | 0.31% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 7.35K | 0.19% | 0.00% | Mar 2026 |
| FMR Inc | 4.74K | 0.12% | 0.00% | Mar 2026 |
| UBS Group AG | 3.39K | 0.09% | +801.86% | Mar 2026 |
| Group One Trading, LLC | 192.00 | 0.01% | 0.00% | Mar 2026 |
| Advisor Group Holdings, Inc. | 130.00 | 0.00% | 0.00% | Mar 2026 |
| Mccormack Advisors International | 100.00 | 0.00% | 0.00% | Mar 2026 |
| Activest Wealth Management | 100.00 | 0.00% | 0.00% | Jun 2026 |
| Citigroup Inc | 89.00 | 0.00% | -98.92% | Mar 2026 |
| WHI TRUST Co LLC | 72.00 | 0.00% | 0.00% | Jun 2026 |
| BNP Paribas Arbitrage, SA | 5.00 | 0.00% | 0.00% | Mar 2026 |
| Caitong International Asset Management Co., Limited. | 4.00 | 0.00% | 0.00% | Mar 2026 |
| Morgan Stanley - Brokerage Accounts | 1.00 | 0.00% | 0.00% | Mar 2026 |
| Kovack Advisors Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Tower Research Capital LLC | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Siren, L.L.C. | 0.00 | 0.00% | -100.00% | Mar 2026 |
Cyclerion Therapeutics Inc company profile
- Company name
- Cyclerion Therapeutics Inc
- Ticker
- CYCN.US
- Exchange
- USA Stocks
- Listed since
- Apr 2, 2019
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1
- Fiscal year end
- December
- Address
- 245 First Street, Riverview II, Cambridge, MA, United States, 02142
- Phone
- 857 327 8778
- Website
- cyclerion.com
About Cyclerion Therapeutics Inc
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Cyclerion Therapeutics Inc management
2- Dr. Regina M. Graul Ph.D.CEO, President & Director · born 1977
- Ms. Rhonda M. Chicko CPAChief Financial Officer · born 1967